Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst TOIIW 深 沪
等待开盘 03-26 09:30:00 美东时间
0.0507
-0.006
-10.42%
华盛通- 最 高0.0556
- 今 开0.0556
- 成交量 3.85万股
- 最 低 0.0402
- 昨 收 0.0566
- 总市值 0
- 52周最高 0.2725
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.0175
- 委 比 -11.11%
- 总股本 --
- 历史最高 3.86
- 量 比 19.58
- 振 幅 27.21%
- 历史最低 0.00
- 每 手 1
- 风险率 0.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多10% owner Jorey Chernett acquires USD 83,750 of The Oncology Institute common shares
10% owner Jorey Chernett acquires USD 83,750 of The Oncology Institute common shares Jorey Chernett, a 10% owner of Oncology Institute, reported buying 25,000 common shares. The reported weighted average purchase price was USD 3.35 per share. Following the transaction, Chernett reported beneficial o
03-23 21:33
Oncology Institute Updates Investors With New Presentation
Oncology Institute ( ($TOI) ) just unveiled an update. The Oncology Institute, ...
03-14 05:50
Why Tempus AI Stock Is Up Wednesday?
Tempus AI shares are trading higher Wednesday after Needham analyst Ryan MacDonald reiterated a Buy rating and maintained a $75 price target.
03-11 22:39
Tempus AI Study Shows Advanced Genomic Profiling Uncovers New Treatment Options For Cancer Patients
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of
03-11 20:42
Tempus AI study finds 12% of community oncology patients gain actionable results from advanced genomic profiling features
Tempus AI study finds 12% of community oncology patients gain actionable results from advanced genomic profiling features Tempus reported a clinical study published in JCO Precision Oncology evaluating advanced features of comprehensive genomic profiling in community oncology settings. The study was
03-11 20:31
The Oncology Institute Appoints Kim Tzoumakas to Board of Directors
The Oncology Institute, Inc. (NASDAQ: TOI) has appointed Kim Tzoumakas to its Board of Directors. With over two decades of experience in oncology, pharmacy services, and healthcare operations, Ms. Tzoumakas has successfully led organizational turnarounds and strategic sales. Her expertise will support TOI's expansion of care delivery models and pharmacy business. TOI, founded in 2007, provides specialized cancer care to approximately 1.9 million ...
02-23 13:00
The Oncology Institute reaffirms 2025 guidance, projects 2026 revenue
The Oncology Institute (TOI) on Monday reaffirmed its 2025 financial guidance and provided its preliminary 2026 outlook, expecting total revenue of $630 million to $650 million, up about 28% from the ...
01-12 21:36
The Oncology Institute Announces Addition of Board Member Mark Stolper
The Oncology Institute, Inc. (TOI) announced the addition of Mark Stolper to its Board of Directors. As RadNet’s CFO and executive vice president, and with extensive healthcare leadership experience, Stolper brings valuable expertise in capital markets and strategic planning to TOI. TOI expects his insights to drive future growth and profitability. Stolper expressed enthusiasm for TOI’s mission to deliver advanced, cost-effective cancer care.
01-05 13:30
The Oncology Institute Announces Resignation of Board Member Gabe Ling
The Oncology Institute, Inc. (TOI) announced that Gabe Ling resigned from its Board of Directors as of December 1, 2025. The company has initiated a search for new independent directors with expertise in healthcare, clinical, and value-based care. The Board expressed gratitude to Ling for his contributions during TOI's development and emphasized its commitment to strengthening governance and achieving long-term growth goals. Founded in 2007, TOI ...
2025-12-01 13:30
Oncology Institute Projects Strong 2025 Revenue Growth
Oncology Institute ( ($TOI) ) just unveiled an update. The Oncology Institute h...
2025-11-14 19:46
